Kinetics of endothelin-1 and effect selective ETA antagonism on ETB activation: a mathematical modeling analysis
Open Access
- 26 November 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1332388
Abstract
Introduction: Endothelin-1 (ET-1) regulates renal and vascular function, but the clinical utility of selective ETA receptor antagonists has been limited due to associated fluid retention. The mechanisms underlying fluid retention remain poorly understood but could be a consequence of changes in ET-1 binding to the unantagonized ETB receptor, either through increased ET-1 or non-selective ETB.Methods: A mathematical model of ET-1 kinetics was developed to quantify effects of ETA antagonist exposure and selectivity on concentrations of ET-1 and its complexes with ETA and ETB receptors. The model describes ET-1 production, tissue and plasma distribution, ETA and ETB receptor binding, and receptor-mediated clearance, and was calibrated and validated with human ET-1 infusion studies.Results: The model confirmed the significant role of ETB in ET-1 clearance. By varying both drug ETA selectivity (Kib/Kia) and concentration over a wide range, simulations predicted that while selective ETA antagonist (selectivity >1) always decreased [ET1-ETA], the change in [ET1-ETB] was more complex. It increased up to 45% as drug concentrations approached and exceeded Kia, but the increase was diminished as drug concentration increased further and fell below baseline at high concentrations. The drug concentration required to cause a decrease in [ET1-ETB] was lower as ETA selectivity decreased.Discussion: This is the first mechanistic mathematical model of ET-1 kinetics that describes receptor-mediated clearance, and the consequence of ETB blockade on ET-1 concentrations. It provides a useful tool that can coupled with experimental studies to quantitively understand and investigate this complex and dynamic system.Keywords
Funding Information
- AstraZeneca
This publication has 29 references indexed in Scilit:
- Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trialThe Lancet, 2019
- Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart FailureJACC: Heart Failure, 2017
- A Tutorial on RxODE: Simulating Differential Equation Pharmacometric Models in RCPT: Pharmacometrics & Systems Pharmacology, 2015
- Increased plasma levels of big-endothelin-2 and big-endothelin-3 in patients with end-stage renal diseaseLife Sciences, 2012
- Quasi-Equilibrium Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug DispositionPharmaceutical Research, 2005
- ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy menClinical Science, 2003
- Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizationsBiochemical Journal, 1997
- Importance measures in global sensitivity analysis of nonlinear modelsReliability Engineering & System Safety, 1996
- Characterization of Peptide and Nonpeptide Antagonists in Human KidneyJournal of Cardiovascular Pharmacology, 1995
- Clearance of Circulating Endothelin-1 by ETB Receptors in RatsBiochemical and Biophysical Research Communications, 1994